C12N 2730/10132
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2730/10132 (Use of virus as therapeutic agent, other than vaccine) appears on 6 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 6
- Published applications
- 7
- Assignees
- 8
- Inventors
- 12
- Latest grant
- 29 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Lipopeptides for use in treating liver diseases and cardiovascular diseases29 Jul 2025US 12,370,237 B2Ruprecht-Karls-UniversitäT Heidelberg
- Lipopeptides for use in treating liver diseases and cardiovascular diseases6 Apr 2021US 10,967,044 B2Ruprecht-Karls-UniversitäT Heidelberg
- Formulations of hepalatide31 Mar 2020US 10,603,352 B2Shanghai Hep Pharmaceutical Co., Ltd.
- Lipopeptides for use in treating liver diseases and cardiovascular diseases17 Sep 2019US 10,413,585 B2Ruprecht-Karls-UniversitäT Heidelberg
- Antiviral resistance mutants and applications thereof20 Jun 2017US 9,682,109 B2A.B.L. S.R.L.
- Lipopeptides for use in treating liver diseases and cardiovascular diseases18 Apr 2024US 2024/0123025 A1Ruprecht-Karls-Universitaet Heidelberg
- Chimeric antigen with enhanced multi-immune function through specific binding to target cell, and use thereof18 Nov 2021US 2021/0355168 A1Rnagene Inc.
- Lipopeptides for Use in Treating Liver Diseases and Cardiovascular Diseases10 Dec 2020US 2020/0384070 A1Ruprecht-Karls-Universitaet Heidelberg
- Lipopeptides for Use in Treating Liver Diseases and Cardiovascular Diseases23 May 2019US 2019/0151406 A1Ruprecht-Karls-Universitaet Heidelberg
- Formulations of hepalatide27 Apr 2017US 2017/0112898 A1Shanghai Hep Pharmaceutical Co., Ltd.
Most cited
By later US patents
- Viral defective interfering particles and uses thereof13US 5,980,901 ABoard of Regents, The University of Texas System · 1999
- Lipopeptides for use in treating liver diseases and cardiovascular diseases1US 10,413,585 B2Ruprecht-Karls-UniversitäT Heidelberg · 2019
- Lipopeptides for use in treating liver diseases and cardiovascular diseases1US 10,967,044 B2Ruprecht-Karls-UniversitäT Heidelberg · 2021